Selected Grants
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome
Clinical TrialPrincipal Investigator · Awarded by Sol-Gel Technologies Ltd. · 2023 - 2026To assess the safety and tolerability of single agent RP1 in selected organ transplant recipients
Clinical TrialPrincipal Investigator · Awarded by Replimune Group, INC · 2021 - 2025An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients with Moderate-to-Severe Atopic Dermatitis
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2023 - 2025A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2019 - 2025A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss ofFunction Mutations
Clinical TrialPrincipal Investigator · Awarded by Endeavor BioMedicines, Inc. · 2023 - 2024A Study to Support Next Generation Sequencing Screening Process of Endeavor Studies in Patients with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Endeavor BioMedicines, Inc. · 2023 - 2024A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, STRATIFIED, VEHICLE-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF SIROLIMUS 3.9% TOPICAL GEL IN PREVENTION OF BCCS IN PATIENTS WITH GORLIN SYNDROME
Clinical TrialPrincipal Investigator · Awarded by Palvella Therapeutics, Inc · 2021 - 2023A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C
Clinical TrialPrincipal Investigator · Awarded by PellePharm · 2020 - 2022Pelle-926-301E: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)
Clinical TrialPrincipal Investigator · Awarded by PellePharm · 2020 - 2021A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C
Clinical TrialPrincipal Investigator · Awarded by PellePharm · 2019 - 2021Qualification of the Methodology to Identify and Measure Basal Cell Carcinomas (BCCs) on the face of patients with Basal Cell Nevus Syndrome (Gorlin Syndrome) or Sporadic BCCs
ResearchPrincipal Investigator · Awarded by PellePharm · 2018 - 2020External Relationships
- Citrus Oncology
- Department of Justice
- Dermotech, LLC
- Regeneron Pharmaceuticals
- Skintelligent
- Sun Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.